Therapeutic Response

PD-L1 >= 1% status confers therapeutic sensitivity to Fluorouracil in combination with Nivolumab and Oxaliplatin in patients with Esophageal Squamous Cell Carcinoma.

Statements

Source and description

Nivolumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell programmed death ligand 1 (PD-L1) expression >= 1%. This regimen specifically cites cisplatin and 5-fluorouracil as the chemotherapy. It also notes that, as the platinum and fluoropyrimidine based chemotherapy is not defined in the EMA licensed indication, other evidence-based platinum and fluoropyrimidine regimens may be used in combination with nivolumab.